Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Adjuvant trastuzumab not thought to add to cardiotoxicity

    • 13 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, Murphy RT.Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 96: 701-707, No. 9, 1 May 2010. Available from: URL: http://dx.doi.org/10.1136/hrt.2009.173997

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Adjuvant trastuzumab not thought to add to cardiotoxicity. React. Wkly. 1309, 3 (2010). https://doi.org/10.2165/00128415-201013090-00007

    Download citation

    Keywords

    • Trastuzumab
    • Anthracycline
    • Diastolic Dysfunction
    • Radial Strain
    • Chemotherapy Group